Lead Compound (undisclosed)

About Stromal Therapeutics

Stromal Therapeutics is an early-stage, privately-held biotech company pioneering a novel approach to treating chronic inflammatory diseases by targeting the tissue stroma. Its platform focuses on locally acting, druggable tissue cytokines, with an initial application in inflammatory heart disease, where no specific therapies currently exist. The company has secured non-dilutive bridge funding from Swiss accelerators BaseLaunch and USZ Innovation to advance its lead candidate towards clinical development, leveraging the strong academic and clinical expertise of its founders.

Therapeutic Areas